Search

Displaying results 1291 - 1300 of 10000 in total
  1. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.

  2. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 4'-N-benzoylstaurosporine
  3. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … [L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis.

  4. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894] … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.

    Mixtures: IMIPENEM/CILASTATINA POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, ARZOMEBA PISA 500MG/500MG (IMIPENEM+CILASTATINA) POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLESynonyms: (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine, (L)-7-(2-Amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid
  5. Drug

    Prilocaine

    go.drugbank.com/drugs/DB00750
    ApprovedInvestigational

    A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)

    Mixtures: LP Lite PAK, Microvix LSynonyms: alpha-n-Propylamino-2-methylpropionanilide, N-(2-Methylphenyl)-2-(propylamino)propanamide
  6. Drug

    Padimate O

    go.drugbank.com/drugs/DB11570
    Approved

    It is a structurally-related compound to [DB02362] that absorbs UV-B rays to prevent photodamage. … Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153].

    Mixtures: Ea Eight Hr Lip Sheer Tints, Skin Pro-tec II SPF-15Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. … Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older.

  8. Drug

    Amiloride

    go.drugbank.com/drugs/DB00594
    ApprovedInvestigational

    This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. … A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells.

    Mixtures: Aa-amilzide, AMILORID HCT ALCategories: Acid Sensing Ion Channel Blockers
  9. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … [A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [

  10. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

    Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors